血清miR-25在肺癌诊断中的临床价值

Clinical diagnostic value of serum miR-25 expression in patients with lung cancer

目的探讨miR-25在不同病理类型肺癌的血清表达量与应用价值及其与临床参数的相关性。方法收集非小细胞肺癌(30例)、小细胞肺癌(28例)、健康人(30例)共88例样本,采用实时定量PCR对血清miR-25含量进行定量检测,并建立受试者工作特征曲线(ROC曲线)计算敏感度及特异度,评价其对肺癌的诊断价值。结果 miR-25在健康人血清表达量比小细胞肺癌组(P=0.000)、非小细胞肺癌组(P=0.001)显著减低,且小细胞肺癌组血清miR-25含量比非小细胞肺癌组明显增高,差异具有统计学意义(P=0.001);进一步建立ROC曲线分析血清miR-25对肺癌的诊断价值,非小细胞肺癌患者的ROC曲线下面积为0.659,敏感度为56.7%,特异度为90%,对应的临界值为1.854;小细胞肺癌的ROC曲线下面积为0.869,敏感度为78.6%,特异度为97%,对应的临界值为2.424。Spearman秩相关表明,血清miR-25表达量与病理分型(r=0.422,P=0.001)、肿瘤分期(r=0.370,P=0.004)、淋巴结转移(r=0.670,P=0.000)、肿瘤标记物(r=0.372,P=0.004)显著相关。结论血清miR-25在肺癌患者中表达量明显升高,尤其是在小细胞肺癌中,可能是小细胞肺癌诊断的一个潜在肿瘤标记物。

Objective To study the expression and application of serum miR-25 in different pathological types of lung cancer, and assess their relationship with clinical factors. Methods Eightyeight serum samples from 30 non-small cell lung cancer, 28 small cell lung cancer and 30 healthy controls were collected as research objects. Serum levels of miR-25 were detected by quantitative real-time PCR analysis. Then the clinical value in the diagnosis of lung cancer was evaluated using ROC curves by calculating sensibility and specificity. Results Serum level of miR-25 was significantly higher in non-small cell lung cancer group(P=0.001) and small cell lung cancer group(P=0.000) than that of healthy control group; the serum level of miR-25 in SCLC was higher than NSCLC, and the differential expression was statistically significant(P=0.001); The area under the ROC curve of NSCLC was 0.659 when 1.854 was selected as the critical value, the sensitivity and specificity were 56.7% and 90% respectively. While the ROC plot derived from SCLC yielded an area under the curve(AUC) of 0.869, the critical value was 2.424, then the sensitivity and specificity were 78.6% and 97% respectively. The spearman rank correlation indicated there was significantly correlation between serum miR-25 and the pathological type(r=0.422, P=0.001), tumor stage(r=0.370, P=0.004), lymph node metastasis(r=0.670, P=0.000), tumor markers(r=0.372, P=0.004). Conclusion Serum miR-25 level is significantly elevated in lung cancer patients, especially SCLC, it may be used as a potential biomarker in diagnosis of lung cancer.